Vident Investment Advisory LLC Purchases 454 Shares of Amgen, Inc. (AMGN)
Vident Investment Advisory LLC raised its position in Amgen, Inc. (NASDAQ:AMGN) by 5.9% during the third quarter, according to its most recent 13F filing with the SEC. The fund owned 8,210 shares of the medical research company’s stock after buying an additional 454 shares during the period. Vident Investment Advisory LLC’s holdings in Amgen were worth $1,531,000 as of its most recent filing with the SEC.
Other institutional investors and hedge funds have also recently made changes to their positions in the company. Baker Ellis Asset Management LLC bought a new position in shares of Amgen in the 3rd quarter worth $108,000. Jackson Grant Investment Advisers Inc. boosted its position in shares of Amgen by 0.8% in the 2nd quarter. Jackson Grant Investment Advisers Inc. now owns 641 shares of the medical research company’s stock worth $110,000 after purchasing an additional 5 shares during the last quarter. Phocas Financial Corp. bought a new position in shares of Amgen in the 2nd quarter worth $110,000. Omnia Family Wealth LLC boosted its position in shares of Amgen by 25.3% in the 2nd quarter. Omnia Family Wealth LLC now owns 729 shares of the medical research company’s stock worth $125,000 after purchasing an additional 147 shares during the last quarter. Finally, Enterprise Financial Services Corp boosted its position in shares of Amgen by 18.0% in the 2nd quarter. Enterprise Financial Services Corp now owns 748 shares of the medical research company’s stock worth $129,000 after purchasing an additional 114 shares during the last quarter. Hedge funds and other institutional investors own 78.59% of the company’s stock.
In other Amgen news, EVP Sean E. Harper sold 1,525 shares of Amgen stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $185.62, for a total value of $283,070.50. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders sold a total of 4,575 shares of company stock worth $814,396 in the last three months. Company insiders own 0.19% of the company’s stock.
Shares of Amgen, Inc. (NASDAQ AMGN) opened at $177.47 on Thursday. Amgen, Inc. has a 12 month low of $152.16 and a 12 month high of $201.23. The stock has a market capitalization of $127,422.84, a PE ratio of 69.05, a price-to-earnings-growth ratio of 2.17 and a beta of 1.42. The company has a quick ratio of 5.17, a current ratio of 5.49 and a debt-to-equity ratio of 1.35.
Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Thursday, February 1st. The medical research company reported $2.89 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $3.03 by ($0.14). Amgen had a net margin of 8.66% and a return on equity of 30.87%. The firm had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.84 billion. During the same period in the prior year, the business earned $2.89 EPS. The business’s revenue for the quarter was down 2.7% compared to the same quarter last year. equities research analysts forecast that Amgen, Inc. will post 13.22 earnings per share for the current fiscal year.
Amgen announced that its board has initiated a stock buyback plan on Wednesday, October 25th that permits the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization permits the medical research company to reacquire shares of its stock through open market purchases. Shares repurchase plans are often a sign that the company’s board of directors believes its stock is undervalued.
The company also recently declared a quarterly dividend, which will be paid on Thursday, March 8th. Shareholders of record on Thursday, February 15th will be paid a $1.32 dividend. This is an increase from Amgen’s previous quarterly dividend of $1.15. The ex-dividend date is Wednesday, February 14th. This represents a $5.28 annualized dividend and a dividend yield of 2.98%. Amgen’s dividend payout ratio (DPR) is currently 178.99%.
WARNING: “Vident Investment Advisory LLC Purchases 454 Shares of Amgen, Inc. (AMGN)” was posted by Daily Political and is the property of of Daily Political. If you are accessing this report on another publication, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this report can be accessed at https://www.dailypolitical.com/2018/02/08/vident-investment-advisory-llc-purchases-454-shares-of-amgen-inc-amgn.html.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.